WO2020150293A1 - Méthode d'assemblage ordonné de molécules d'adn circulaires et linéaires - Google Patents

Méthode d'assemblage ordonné de molécules d'adn circulaires et linéaires Download PDF

Info

Publication number
WO2020150293A1
WO2020150293A1 PCT/US2020/013587 US2020013587W WO2020150293A1 WO 2020150293 A1 WO2020150293 A1 WO 2020150293A1 US 2020013587 W US2020013587 W US 2020013587W WO 2020150293 A1 WO2020150293 A1 WO 2020150293A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
circular
exonuclease
minutes
molecule
Prior art date
Application number
PCT/US2020/013587
Other languages
English (en)
Inventor
Charles J. BIEBERICH
Xiang Li
Original Assignee
University Of Maryland, Baltimore County
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore County filed Critical University Of Maryland, Baltimore County
Priority to EP20741848.4A priority Critical patent/EP3911750A4/fr
Priority to JP2021538374A priority patent/JP7332699B2/ja
Priority to AU2020209757A priority patent/AU2020209757B2/en
Priority to CA3125347A priority patent/CA3125347A1/fr
Priority to US17/419,893 priority patent/US20220090090A1/en
Publication of WO2020150293A1 publication Critical patent/WO2020150293A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses

Definitions

  • the present invention relates to a method of assembling circular and linear DNA molecules, more specifically, the present invention provides for a homology-based, one-tube assembly method including a non-linearized circular DNA vector and at least one restriction enzyme for assembling the circular and linear DNA molecules.
  • Cloning a specific gene into a circular plasmid vector is often the first step in studying gene functions.
  • gene cloning has been achieved by digesting the target gene and the vector with restriction endonucleases followed by ligating them together by using a DNA ligase. This process can be technically challenging especially when the target gene to be cloned is generated by PCR.
  • the main hurdle for cloning PCR products is the often low efficiency of restriction enzyme digestion of PCR products.
  • The“Gibson Assembly” method starts with linearized vectors and uses three types of enzymes in the same reaction: T5 exonuclease, Phusion DNA polymerase and Taq ligase [1]
  • The“In-Fusion” method uses a similar strategy, however no Taq ligase is used [2] These strategies can assemble multiple DNA fragments into one plasmid DNA vector with high efficiency.
  • Another method was recently described in which only T5 exonuclease is required to perform the assembly [3] However, in all of the strategies described above, linearization of the circular plasmid DNA prior to the assembly reaction is required.
  • the present invention provides a method to assemble circular or linear DNA molecules wherein a circular DNA vector is directly assembled with a linear nucleotide product in one step and in one reaction vessel.
  • the present invention provides for a one pot method to prepare a circular or linear DNA molecule for use in preparing a nucleotide end-product, the method comprising:
  • reaction vessel a combination of a circular DNA vector and a linearized target DNA molecule with regions of sequence having homology to the vector on both ends; introducing into the reaction vessel at essentially the same time the circular DNA vector and the amplified linearized target DNA molecule and at least one restriction enzyme into the reaction vessel in an amount to linearize the circular DNA vector;
  • the buffering solution comprises at least a DNA polymerase, a 5'-3' exonuclease, a buffering agent and optionally a DNA ligase;
  • nucleotide end-product is selected from the group consisting of circular or linear DNA molecule, circular or linear RNA molecule or a protein encoded by the circularized or linearized DNA molecule through host cell production.
  • the linearized target DNA molecule can be amplified and then the linearized target DNA molecule is ready for the combination.
  • the DNA target molecule may include a single strand of nucleotides on both the 5’ and 3’ end corresponding to the DNA nucleotide single strands on the linearized circular DNA vector caused by the specific restriction enzyme used in the cutting process within the one pot system.
  • the target DNA target molecule can be hybridized to the overlapping complementary single stranded DNA region on linearize circular DNA molecule once the circular DNA vector is linearized.
  • the linearized target DNA molecule may in some embodiments comprise multiple DNA fragments that are combined and wherein each such DNA fragment will include overlapping single stranded DNA ends that overlaps with the single stranded DNA ends of the next fragment and then the ends of the combination of fragments will overlap or have homology with the end sequences of the cut circular vector.
  • DNA polymerases that work in the methods of joining such fragments are those having intrinsic exonuclease activity and are capable of performing the DNA joining reaction of the invention. Such polymerases have the ability to join two linear DNA molecules having ends with complementary nucleotide sequences.
  • the DNA polymerases of the invention are either commercially available or may be prepared using standard recombinant DNA technology.
  • the DNA polymerases useful in the joining the fragments have intrinsic 3'-5' exonuclease activity or 5'-3' exonuclease activity.
  • the DNA ligase is a thermostable DNA ligase, such as Taq DNA ligase (New England Biolabs), 9N DNA ligase (New England Biolabs) or Ampligase (Illumina, San Diego, Calif.), preferably Taq ligase is used.
  • any DNA polymerase enzyme can be used for the polymerase cycling assembly reaction in a method of the present invention.
  • the DNA polymerase is a high-fidelity DNA polymerase, meaning that the DNA polymerase has a proof-reading function such that the probability of introducing a sequence error into the resulting, intact nucleic acid molecule is low.
  • DNA polymerases suitable for the polymerase cycling assembly reaction include, but are not limited to Phusion polymerase, platinum Taq DNA polymerase High Fidelity (Invitrogen), Pfu DNA polymerase, etc.
  • the DNA polymerase used in the PCR is a thermostable, high-fidelity DNA polymerase, such as Phusion DNA polymerase (New England Biolabs, Ipswich, Mass.).
  • the buffering solution comprises at least a crowding agent such as a PEG molecule, and other components including but not limited to components selected from a group consisting of potassium acetate, magnesium acetate, bovine serum albumin, dNTPs, and buffer agents, such as a Tris buffering agent.
  • a crowding agent such as a PEG molecule
  • other components including but not limited to components selected from a group consisting of potassium acetate, magnesium acetate, bovine serum albumin, dNTPs, and buffer agents, such as a Tris buffering agent.
  • the buffering solution comprises 2% to 10% of PEG8000, 50 mM to about 150 mM of Tris- Acetate, a pH 6.5 to 8.5, about 0.09 mM to about 0.4 mM dNTPs, about 25 mM to about 75 mM of potassium acetate, about 10 mM to about 40 mM of magnesium acetate and about 50 mg/ml to about 150 mg/ml Bovine Serum Albumin. More preferably the buffer solution comprises about 5% PEG8000, about 100 mM Tris-Acetate, a pH 8, about 0.2 mM dNTPs, about 50 mM of potassium acetate, about 20 mM of magnesium acetate and about 100 mg/ml Bovine Serum Albumin.
  • the incubating time is preferably divided into at least two different time periods and temperature regimes to linearize the circular plasmid and produce the circularized or linearized DNA molecule.
  • the first time period and temperature may be from about 32°C to about 40°C for about 10 minutes to about 20 minutes and more preferably with a temperature of about 37°C for about 15 minutes.
  • the next period and temperature are from about 45°C to about 55°C for about 10 minutes to about 20 minutes and more preferably with a temperature of about 50°C for about 15 minutes.
  • other temperatures and time periods have been found effective such as 50°C for 60 minutes; 37°C for 15 minutes+ 50°C for 45 minutes and 37°C for 30 minutes + 50°C for 30 minutes
  • restriction enzymes can include those that produce blunt ends (e.g., Smal, Stul, Seal, EcoRV) or 3' overhangs (e.g., Notl, BamHI, EcoRI, Spel, Xbal, Haelll, Taql, Alul) In some situations, other restriction endonucleases that produce 5' overhangs can also be used.
  • the present invention provides for a one pot method to prepare a circular or linear DNA molecule, the method comprising:
  • reaction vessel a circular plasmid with a known nucleotide sequence and a PCR amplified product of a linearized target DNA molecule with a known nucleotide sequence for encoding a desired target protein
  • the incubation solution comprises components comprising at least a DNA polymerase, a 5’ -3’ exonuclease, a buffering solution comprising at least a crowding agent such as a PEG molecule, and other components including but not limited to dNTPs, a tris buffering agent, and optionally a DNA ligase;
  • incubating the components at a temperature and for a sufficient time for linearization of the circular plasmid and joining the PCR amplified product and a linearized circular plasmid for production of a circularized or linearized DNA molecule for subsequent expression in a host cell wherein the incubation time and temperature is selected from the group 37°C for 15 minutes + 50°C for about 15 minutes; 50°C for 60 minutes; 37°C for 15 minutes+ 50°C for 45 minutes and 37°C for 30 minutes + 50°C for 30 minutes.
  • the present invention provides for a one pot method to prepare a circular or linear DNA molecule, the method comprising:
  • reaction vessel a circular plasmid and a PCR amplified product of a linearized target DNA molecule encoding a desired target protein
  • the buffering solution comprises at least a DNA polymerase, a 5'-3' exonuclease, a buffering agent and optionally a DNA ligase;
  • the present invention provides for a composition for a one pot synthesis of a circularized or linearized DNA molecule, the composition comprising;
  • a circular plasmid a linearized target DNA molecule, at least one restriction enzyme, and preferably two restriction enzymes, at least a DNA polymerase, a 5’- 3’ exonuclease, an incubating solution comprising a PEG molecule as a crowding agent, and other components including but not limited to dNTPs, a tris buffering agent, and optionally a DNA ligase.
  • the linearized DNA target molecule can be amplified for inclusion in the composition.
  • kits suitable for directionally cloning a linearized DNA target product into a circular DNA vector may comprise, in separate containers for adding to a single reaction vessel, an aliquot of a DNA polymerase having intrinsic exonuclease activity that is capable of performing the DNA joining reaction of the amplified products into a circular DNA vector, at least one restriction enzyme that may be in a separate container for adding to the reaction vessel and an aliquot of reaction buffer.
  • An aliquot refers to an amount of the component sufficient to perform at least one program of cloning.
  • the DNA polymerase may be provided as a solution of known concentration such a buffer solution that include other reagents wherein such reagents may include, together or in separate containers, PEG molecule as a crowding agent, and other components including but not limited to dNTPs, a tris buffering agent, and optionally a Taq ligase.
  • Figure 1 shows the process for assembling a gene into a vector used by Prior Art Methods.
  • Figure 2 shows the one-step assembly of circular vector DNA with target DNA of the present invention.
  • Figure 3 shows the colony PCR screen for clones with the correct insert.
  • Figure 4 shows a schematic of the invention with homology stitching oligos.
  • the present invention has multiple advantages over the existing methods.
  • the first advantage is that it is less time consuming.
  • the prior art method used pre-linearized DNA circular vectors and such restriction digestion of the vector DNA often takes 20 minutes to one hour.
  • restriction enzyme digestion of vector DNA is often incomplete as shown in Figure 1. Trace amounts of incompletely digested vector DNA creates false positive clones that do not contain the target DNA molecule.
  • It is technically extremely difficult to achieve successful assembly using the Gibson method if the vector is digested with a single restriction enzyme due to the rapid and preferential intramolecular re-ligation of the vector to itself during the assembly reaction. This is especially a problem when the assembly reaction is inefficient, for example, when joining multiple fragments is required to create the correct insert.
  • the next step in the prior art often entails requires electrophoresis of the DNA which may take at least one hour including the time to prepare the agarose gel.
  • Purifying the prior art prelinearized vector DNA from the gel often takes more than 30 minutes.
  • Other methods include precipitation and resuspending after restriction digestion.
  • the present invention avoids all the above described time consuming steps and more importantly the high costs of such steps, such as the cost of agarose gel electrophoresis and the reagents for gel purification of vector DNA. Further, the method of the present invention makes it easier to achieve a high concentration of vector DNA in the reaction by eliminating the dilution and re-concentration steps necessitated by prior restriction digestion, gel electrophoresis and gel purification. High vector concentration is desirable since it markedly increases the number of positive clones obtained when the assembled DNA is transformed into bacteria cells.
  • the largest advantage of the present invention is lower background which is achieved by the continuous presence of the restriction enzyme in the novel and inventive system thereby allowing the dynamic digestion of self-ligated vector and greatly reducing the background.
  • 5'-3' exonuclease refers to an exonuclease that degrades DNA from the 5' end, i.e., in the 5' to 3' direction.
  • 5'-3' exonucleases of interest can remove nucleotides from the 5' end of a strand of ds DNA at a blunt end and, in certain embodiments, at a 3' and or 5' overhang.
  • T5 exonuclease, lambda exonuclease and T7 exonuclease are examples of 5'- 3' exonucleases.
  • T5 exonuclease is preferred.
  • T5 exonuclease additionally has a ss endonuclease activity.
  • ligase refers to an enzyme that can covalently join a 3' end of a DNA molecule to a 5' end of another DNA molecule, particularly at a nick.
  • ligases include T7 ligase, T4 DNA ligase, E. coli DNA ligase and Taq ligase, although many others are known and may be used herein.
  • overlapping sequence refers to a sequence that is complementary in two polynucleotides and where the overlapping sequence is ss, on one polynucleotide it can be hybridized to another overlapping complementary ss region on another polynucleotide.
  • overhang refers to the single stranded region of ds DNA at the end thereof and is either of type 5' or 3' due to the inherent directionality of DNA.
  • the overhangs are generally generated in various lengths by treating dsDNA with restriction enzymes or exonucleases and/or by the addition of appropriate dNTPs (dATP, dTTP, dCTP, dGTP).
  • single strand (ss) DNA binding protein refers to proteins that bind to ss DNA and prevent premature annealing, protect the ss DNA from being digested by nucleases, and polymerases and/or remove secondary structure from the DNA to allow other enzymes to function effectively upon it. Inclusion of a ss binding protein in the compositions described herein is preferable to optimize the efficiency of synthon formation.
  • ss DNA binding proteins are T4 gene 32 protein, E.
  • coli SSB T7 gp2.5 SSB, and phage phi29 SSB, and ET SSB although many others, e.g., RedB of lambda phage, RecT of Rac prophage and the sequences listed below, are known and may be used herein.
  • dsDNA double stranded DNA
  • dsDNA refers to oligonucleotides or polynucleotides having 3' overhang, 5' overhang or blunt ends and composed of two single strands all or part of which are complementary to each other, and thus dsDNA may contain a single stranded region at the ends and may be synthetic or natural origin derived from cells or tissues.
  • dsDNA is a product of PCR (Polymerase Chain Reaction) or fragments generated from genomic DNA or plasmids or vectors by a physical or enzyme treatment thereof.
  • buffering agent refers to an agent that allows a solution to resist changes in pH when acid or alkali is added to the solution.
  • suitable non-naturally occurring buffering agents include, for example, Tris, HEPES, TAPS, MOPS, tricine, or MES.
  • polynucleotide encompasses oligonucleotides and refers to a nucleic acid of any length.
  • Polynucleotides may be DNA or RNA.
  • Polynucleotides may be ss or ds unless specified.
  • Polynucleotides may be synthetic, for example, synthesized in a DNA synthesizer, or naturally occurring, for example, extracted from a natural source, or derived from cloned or amplified material.
  • Polynucleotides referred to herein may contain modified bases.
  • the target nucleic acids utilized herein can be any nucleic acid, for example, human nucleic acids, bacterial nucleic acids, or viral nucleic acids.
  • the target nucleic acid sample can be, for example, a nucleic acid sample from one or more cells, tissues, or bodily fluids such as blood, urine, semen, lymphatic fluid, cerebrospinal fluid, or amniotic fluid, or other biological samples, such as tissue culture cells, buccal swabs, mouthwashes, stool, tissues slices, biopsy aspiration, and archeological samples such as bone or mummified tissue.
  • Target nucleic acids can be, for example, DNA, RNA, or the DNA product of RNA subjected to reverse transcription.
  • Target samples can be derived from any source including, but not limited to, eukaryotes, plants, animals, vertebrates, fish, mammals, humans, non-humans, bacteria, microbes, viruses, biological sources, serum, plasma, blood, urine, semen, lymphatic fluid, cerebrospinal fluid, amniotic fluid, biopsies, needle aspiration biopsies, cancers, tumors, tissues, cells, cell lysates, crude cell lysates, tissue lysates, tissue culture cells, buccal swabs, mouthwashes, stool, mummified tissue, forensic sources, autopsies, archeological sources, infections, nosocomial infections, production sources, drug preparations, biological molecule productions, protein preparations, lipid preparations, carbohydrate preparations, inanimate objects, air, soil, sap, metal, fossils, excavated materials, and/or other terrestrial or extra terrestrial materials and sources.
  • eukaryotes plants, animals, vertebrates, fish, mammals, humans, non-
  • the sample may also contain mixtures of material from one source or different sources.
  • nucleic acids of an infecting bacterium or virus can be amplified along with human nucleic acids when nucleic acids from such infected cells or tissues are amplified using the disclosed methods.
  • Types of useful target samples include eukaryotic samples, plant samples, animal samples, vertebrate samples, fish samples, mammalian samples, human samples, non human samples, bacterial samples, microbial samples, viral samples, biological samples, serum samples, plasma samples, blood samples, urine samples, semen samples, lymphatic fluid samples, cerebrospinal fluid samples, amniotic fluid samples, biopsy samples, needle aspiration biopsy samples, cancer samples, tumor samples, tissue samples, cell samples, cell lysate samples, crude cell lysate samples, tissue lysate samples, tissue culture cell samples, buccal swab samples, mouthwash samples, stool samples, mummified tissue samples, autopsy samples, archeological samples, infection samples, nosocomial infection samples, production samples, drug preparation samples, biological molecule production samples, protein preparation samples, lipid preparation samples, carbohydrate preparation samples, inanimate object samples, air samples, soil samples, sap samples, metal samples, fossil samples, excavated material samples, and/or other terrestrial or extra-terrestrial samples.
  • Types of forensics samples include blood, dried blood, bloodstains, buccal swabs, fingerprints, touch samples (e.g., epithelial cells left on the lip of a drinking glass, the inner rim of a baseball cap, or cigarette butts), chewing gum, gastric contents, saliva, nail scrapings, soil, sexual assault samples, hair, bone, skin, and solid tissue.
  • Types of environmental samples include unfiltered and filtered air and water, soil, swab samples from surfaces, envelopes, and powders.
  • overlapping sequence refers to a sequence that is complementary in two polynucleotides and where the overlapping sequence is ss, on one polynucleotide it can be hybridized to another overlapping complementary ss region on another polynucleotide.
  • the overlapping sequence may be complementary in at least 5, 10, 15, or more polynucleotides in a set of polynucleotides.
  • An overlapping sequence may vary in length and, in some cases, may be at least 12 nucleotides in length (e.g. at least 15, 20 or more nucleotides in length) and/or may be up 100 nucleotides in length (e.g., up to 50, up to 30, up to 20 or up to 15 nucleotides in length).
  • polynucleotide assembly refers to a reaction in which two or more, four or more, six or more, eight or more, ten or more, 12 or more 15 or more polynucleotides, e.g., four or more polynucleotides are joined to another to make a longer polynucleotide.
  • the product of a polynucleotide assembly reaction i.e., the "assembled polynucleotide” in many embodiments should contain one copy of each of the overlapping sequences.
  • reaction conditions suitable for the enzymes and reagents used in the present method are described herein and, as such, suitable reaction conditions for the present method can be readily determined. These reactions conditions may change depending on the enzymes used (e.g., depending on their optimum temperatures, etc.).
  • Phusion polymerase refers to thermal stable DNA polymerase that contains a Pyrococcus- like enzyme fused with a processivity-enhancing domain, resulting in increased fidelity and speed, e.g., with an error rate >50-fold lower than that of Tag DNA Polymerase and 6-fold lower than that of Pyrococcus furiosus DNA Polymerase. It possesses 5' - 3' polymerase activity and an example of Phusion polymerase is Phusion®. High-Fidelity DNA Polymerase (New England Biolabs).
  • joining refers to the production of covalent linkage between two sequences.
  • primer refers to a bipartite primer or a primer having a first and second portion.
  • a first portion of the primer is designed to be complementary to the appropriate end of a target DNA molecule and a second portion of the primer is designed to be complementary to nucleotide sequences on one side of the chosen restriction site of the circular plasmid, once linearized in the buffer solution of the present invention.
  • Bipartite primers will generally have a minimum length of about 10 nucleotides and a maximum length of about 200 nucleotides and preferably about from 20 nucleotides to about 100 nucleotides, more preferably from about 30 nucleotides and about 40 nucleotides.
  • composition refers to a combination of reagents that may contain other reagents, e.g., glycerol, salt, dNTPs, etc., in addition to those listed.
  • a composition may be in any form, e.g., aqueous or lyophilized, and may be at any state (e.g., frozen or in liquid form).
  • any one or more of the proteins used herein may be temperature sensitive or thermostable where, as used herein, the term “temperature sensitive” refers to an enzyme that loses at least 95% of its activity after 10 minutes at a temperature of 65°C., and the term “thermostable” refers to an enzyme that retains at least 95% of its activity after 10 minutes at a temperature of 65°C.
  • the steps of the invention initially include attaching a primer to the linearized target nucleotide molecule.
  • the linear target nucleotide molecule can be amplified by using the polymerase chain reaction with a first and second primers to provide a PCR amplified product.
  • the 3' end of the first primer molecule is designed to hybridize with the first end of the target DNA molecule, and the 5' end of the first primer molecule has a sequence designed to incorporate sequences in the final PCR product that are complementary to the first end of the linearized plasmid DNA molecule after the circular plasmid interacts with a appropriate restriction enzyme to cut it at the chosen insert site.
  • the 3' end of the second primer is designed to hybridize with the second end of the target DNA molecule, and the 5' end of the second primer molecule has a sequence designed to incorporate sequences in the final PCR product that are complementary to the second end of the linearized plasmid DNA molecule after interaction with the appropriate restriction enzyme.
  • the two primers are then annealed to the target DNA molecule which is then PCR amplified using standard conditions to generate a PCR amplified product.
  • the PCR amplified product is then simultaneously incubated with the circular plasmid in the presence of the appropriate restriction enzymes to cut it at the chosen insert sites using standard conditions, a suitable reaction buffer and in the presence of a DNA polymerase that is capable of performing the DNA joining reaction of the invention, for about 5 to about 60 minutes, preferably from about 10 to about 40 minutes, most preferably from about 15 to about 30 minutes.
  • the reaction buffer may be any buffer that is used in DNA annealing reactions.
  • the temperature may be in the range of from about 35-40°C, more preferably about 37°C.
  • the method of the invention may be used to clone any variety or number of target DNA molecules.
  • size is the capacity of the circular DNA vector to carry the insert in transformation and replication in the host cell.
  • Any circular DNA vector capable of replicating in a prokaryotic or eukaryotic cell is usable with the present invention.
  • the choice of circular DNA vector, such as capsid, cosmid or bacterial artificial chromosome depends on the functional properties desired, for example, protein expression, and the host cell to be transformed.
  • the circular DNA vector has a known sequence of about 5 to about 100, preferably about 8 to about 50, most preferably about 10 to about 35 nucleotides, on either side of the chosen restriction enzyme site.
  • pairs of single stranded oligonucleotides can be used to generate a region of sequence overlap between the vector and the target DNA molecule or between two target DNA molecules that includes additional nucleotides not found in the vector or the target DNA, e.g. when it is desirable to add a promoter sequence or the DNA sequence encoding a tag for a protein such as shown in Figure 4
  • Typical expression circular plasmids contain a promoter, an enhancer, a coding sequence and a terminator.
  • the promoter region of the plasmid binds RNA polymerase II, associated enzymes and other factors, which are required to initiate transcription.
  • the function of enhancer sequences is to bind specific intracellular transcription factors.
  • the DNA-bound transcription factors interact with the transcription complex and increased the transcription rate.
  • Normal endogenous transcription factors are proteins that contain two domains, the DNA binding domain and the transcription activation domain.
  • the DNA binding domain binds to specific duplex DNA sequences, usually 5-10 base pairs, located in the enhancer region. The DNA binding domain brings the transcription activation domain into proximity of the minimal promoter where it interacts with RNA polymerase to activate transcription.
  • the present examples utilized a commercially available plasmid with a selectable marker. Any selectable marker may be used. Similarly a specific recognition site for any restriction cleavage enzyme capable of specifically cleaving at the ends of the oligonucleotide to generate either staggered ends or blunt ends may be selected where the specific cleavage site does not occur in the fragments of interest in addition to the engineered position adjacent to the ends of the fragment of interest.
  • the recognition site for the restriction enzyme that produces staggered ends has been introduced adjacent to the polynucleotide of interest by means of DNA synthesis.
  • the reaction mixture obtained from the incubation of DNA polymerase and restriction enzyme with the circular plasmid and the PCR amplified product may be used to transform any host cell using standard transformation procedures.
  • Such hosts can be, in particular, bacteria or eukaryotic cells (yeasts, animal cells, plant cells), and the like.
  • bacteria Escherichia coli, Bacillus subtilis, Streptomyces, Pseudomonas (P. putida, P.
  • aeruginosa Rhizobium meliloti
  • Agrobacterium tumefaciens Staphylococcus aureus
  • Streptomyces pristinaespirais Enterococcus faecium or Clostridium , and the like
  • bacteria E. coli is commonly used.
  • yeasts Kluyveromyces, Saccharomyces, Pichia, Hansenula , and the like, may be mentioned.
  • mammalian animal cells CHO, COS, NIH3T3, and the like, may be mentioned.
  • the selection marker gene may be a resistance gene, for example, conferring resistance to an antibiotic (ampicillin, kanamycin, geneticin, hygromycin, and the like), or any gene endowing the cell with a function, which it no longer possesses (for example, a gene which has been deleted on the chromosome or rendered inactive), the gene on the plasmid reestablishing this function.
  • This selectable marker gene allows plasmid selection and production in minimal media.
  • the circular DNA is a plasmid which uses the vector pQE80L as a backbone and contains human RPS6 gene.
  • the linear PCR product is human SRSF3, and the primers used to amplify SRSF3 genes are: GCATCACCATCACCATCACGtgcatcgtgattcctgtcc (SEQ ID NO: 1) and TAATTAAGCTTGGCTGCAGGctatttcctttcatttgacc (SEQ ID NO 2). Each primer has a 20- base pair homology with the vector.
  • SRSF3 gene is amplified using HeLa cell cDNA as template.
  • plasmid DNA is mixed with 300 ng of PCR product and mixed with 1 ul of BamHI and 1 ul of Sail together with a buffer plus Phusion Taq polymerase, Taq ligase and T5 exonuclease.
  • the mixture is incubated at 37°C for 15 minutes then 50°C for 45 minutes to assemble SRSF3 into pQE80L.
  • the reaction mixture is passed through a column to remove salts and the DNA was used to transform E. coli DH10B competent cells.
  • the colonies are screened with colony PCR. 8 colonies were picked from the plates and screened with colony PCR using the same primers. Plasmids purified from all 8 colonies contain the correct insert and shown in Figure 3. Arrow shows correct sized insert.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode d'assemblage de molécules D'ADN circulaires et linéaires, et concerne plus particulièrement une méthode basée sur l'homologie, un procédé d'assemblage à tube unique comprenant un vecteur d'ADN circulaire et au moins une enzyme de restriction sans linéarisation préalable d'un tel vecteur d'ADN circulaire.
PCT/US2020/013587 2019-01-15 2020-01-15 Méthode d'assemblage ordonné de molécules d'adn circulaires et linéaires WO2020150293A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20741848.4A EP3911750A4 (fr) 2019-01-15 2020-01-15 Méthode d'assemblage ordonné de molécules d'adn circulaires et linéaires
JP2021538374A JP7332699B2 (ja) 2019-01-15 2020-01-15 環状及び線状ｄｎａ分子を規則正しく構築する方法
AU2020209757A AU2020209757B2 (en) 2019-01-15 2020-01-15 A method for assembling circular and linear DNA molecules in an ordered manner
CA3125347A CA3125347A1 (fr) 2019-01-15 2020-01-15 Methode d'assemblage ordonne de molecules d'adn circulaires et lineaires
US17/419,893 US20220090090A1 (en) 2019-01-15 2020-01-15 A method for assembling circular and linear dna molecules in an ordered manner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962792532P 2019-01-15 2019-01-15
US62/792,532 2019-01-15

Publications (1)

Publication Number Publication Date
WO2020150293A1 true WO2020150293A1 (fr) 2020-07-23

Family

ID=71613363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/013587 WO2020150293A1 (fr) 2019-01-15 2020-01-15 Méthode d'assemblage ordonné de molécules d'adn circulaires et linéaires

Country Status (6)

Country Link
US (1) US20220090090A1 (fr)
EP (1) EP3911750A4 (fr)
JP (1) JP7332699B2 (fr)
AU (1) AU2020209757B2 (fr)
CA (1) CA3125347A1 (fr)
WO (1) WO2020150293A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324839B2 (en) 2019-09-18 2022-05-10 Intergalactic Therapeutics, Inc. b Synthetic DNA vectors and methods of use
WO2023147547A1 (fr) * 2022-01-31 2023-08-03 Integrated Dna Technologies, Inc. Procédés et compositions d'assemblage d'adn basé sur la recombinaison

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7490330B2 (ja) 2018-06-27 2024-05-27 三菱重工サーマルシステムズ株式会社 フィルタ清掃ユニット及び空気調和機

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036088A1 (fr) * 1998-12-17 2000-06-22 Yuri Romantchikov Procedes ameliores d'insertion d'acides nucleiques dans des vecteurs circulaires
WO2007021944A2 (fr) * 2005-08-11 2007-02-22 The J. Craig Venter Institute Methode de recombinaison in vitro
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
US9206433B2 (en) * 2013-05-01 2015-12-08 Dna Twopointo, Inc. Methods, compositions and kits for a one-step DNA cloning system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004004491T2 (de) * 2003-12-04 2007-12-13 Roche Diagnostics Gmbh Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden
US8968999B2 (en) * 2008-02-15 2015-03-03 Synthetic Genomics, Inc. Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
US9361427B2 (en) * 2011-02-01 2016-06-07 The Regents Of The University Of California Scar-less multi-part DNA assembly design automation
WO2018203056A1 (fr) * 2017-05-03 2018-11-08 Oxford University Innovation Ltd. Assemblage d'adn

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000036088A1 (fr) * 1998-12-17 2000-06-22 Yuri Romantchikov Procedes ameliores d'insertion d'acides nucleiques dans des vecteurs circulaires
US7575860B2 (en) * 2000-03-07 2009-08-18 Evans David H DNA joining method
WO2007021944A2 (fr) * 2005-08-11 2007-02-22 The J. Craig Venter Institute Methode de recombinaison in vitro
US9206433B2 (en) * 2013-05-01 2015-12-08 Dna Twopointo, Inc. Methods, compositions and kits for a one-step DNA cloning system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ENGLER C; KANDZIA R; MARILLONNET S: "A one pot, one step, precision cloning method with high throughput capability", PLOS ONE, vol. 3, no. 11, 30 November 2008 (2008-11-30), pages 1 - 7, XP002613221, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0003647 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324839B2 (en) 2019-09-18 2022-05-10 Intergalactic Therapeutics, Inc. b Synthetic DNA vectors and methods of use
US11602569B2 (en) 2019-09-18 2023-03-14 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
US11684680B2 (en) 2019-09-18 2023-06-27 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
US11766490B2 (en) 2019-09-18 2023-09-26 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
WO2023147547A1 (fr) * 2022-01-31 2023-08-03 Integrated Dna Technologies, Inc. Procédés et compositions d'assemblage d'adn basé sur la recombinaison

Also Published As

Publication number Publication date
EP3911750A4 (fr) 2022-09-28
US20220090090A1 (en) 2022-03-24
EP3911750A1 (fr) 2021-11-24
AU2020209757A1 (en) 2021-07-15
AU2020209757B2 (en) 2023-03-02
JP7332699B2 (ja) 2023-08-23
CA3125347A1 (fr) 2020-07-23
JP2022522397A (ja) 2022-04-19

Similar Documents

Publication Publication Date Title
CN114410625B (zh) 通过Cas9-crRNA复合物的RNA指导的DNA裂解
AU2020209757B2 (en) A method for assembling circular and linear DNA molecules in an ordered manner
US9012183B2 (en) Use of template switching for DNA synthesis
US7615625B2 (en) In vitro amplification of nucleic acid molecules via circular replicons
JP6594955B2 (ja) シントン形成
JP6701450B2 (ja) Ｄｎａの産生方法及びｄｎａ断片連結用キット
JP5628664B2 (ja) 相同組換え方法およびクローニング方法並びにキット
US20030082578A1 (en) In vitro amplification of nucleic acid molecules via circular replicons
KR102491725B1 (ko) 환상 dna의 복제 또는 증폭 방법
US20080182296A1 (en) Pcr-directed gene synthesis from large number of overlapping oligodeoxyribonucleotides
JP2023522848A (ja) 改善された部位特異的改変のための組成物及び方法
US20230002754A1 (en) Vitro Cleavage of DNA Using Argonaute
EP0807186A1 (fr) Procedes destines a l'amplification isotherme de molecules d'acide nucleique
EP1546313A1 (fr) Ligase d'arn thermostable provenant d'un bacteriophage thermus
AU2004276790A1 (en) Methods of synthesizing polynucleotides using thermostable enzymes
CA2837503C (fr) Ribunuclease h issue du genie genetique a specificite de sequence et procede pour determiner la preference de sequence de proteine de liaison d'hybride adn-arn
WO2005045073A1 (fr) Procede permettant d'amplifier une sequence d'adn inconnue adjacente a une sequence connue
KR20240049306A (ko) Ruvc 도메인을 갖는 효소
JP2002253265A (ja) 改変された耐熱性ｄｎａポリメラーゼ
WO2022214522A2 (fr) Compositions et procédés de modification spécifique à un site
JP2001017172A (ja) 二本鎖ｄｎａ断片の末端での連結
JP2003533979A (ja) Ｄｎａの連結方法
JP7125727B1 (ja) 核酸配列改変用組成物および核酸配列の標的部位を改変する方法
US6586237B1 (en) Compositions and methods for cloning nucleic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20741848

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021538374

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3125347

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020209757

Country of ref document: AU

Date of ref document: 20200115

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020741848

Country of ref document: EP

Effective date: 20210816